Enabling Surgical Pocket REgeneration

Informations projet

ESPREE

N° de convention de subvention: 946140

DOI

10.3030/946140

Projet clôturé

Date de signature de la CE 20 Avril 2020

Date de début 1 Mai 2020

Date de fin 30 Avril 2023

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 2 134 093,75

Contribution de l’UE

€ 1 493 865,00

Coordonné par

HYLOMORPH AG
Switzerland

Periodic Reporting for period 2 - ESPREE (Enabling Surgical Pocket REgeneration)

Période du rapport: 2021-05-01 au 2023-04-30

Résumé du contexte et des objectifs généraux du projet

All medical devices implanted into the human body are perceived as foreign objects, resulting in an attempt by the body to reject them through a process called foreign body reaction. This can result in either the failure of the medical device and/or significant clinical complications. Hylomorph has developed Hylomate, the world's first solution to protect all implantable medical devices in contact with soft tissues from foreign body reaction, acting as an "invisibility" cloak through complex interactions at the microscopic level with the surrounding tissue.

Hylomate is a platform technology that addresses all causes of severe complications connected to the implantation of synthetic materials. It ensures an all-round protection of the surgical pocket, preventing infection, hematoma, foreign body reaction and fibrotic encapsulation. Hylomate increases the lifespan of implants and minimizes exposure to life-threatening risk. This results in (1) improve quality - of - life for patients (2) better quality-of-care for healthcare providers and (3) reduced health economics burden. The first application for Hylomate will be in the field of cardiac rhythm management in combination with pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices.

The completion of ESPREE will put Hylomorph in the position to successfully pursue an additional financing round, to set-up sales and marketing forces in the US and Europe to demonstrate commercial traction of Hylomate during the showcasing phase.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

35 patients have been implanted for more than 1 year, having completed the full course of Visits (Visit 1 to Visit 4). The longest implant has now reached 38 months. The overall monitoring of the implant recipient’s health confirms the general optimal safety profile of the Hylomate. Next to the PI’s opinion, the DSMB has reviewed the 1 year follow up data of all the patients and adjudicated that no device related adverse events occurred in the study.
Overall, the clinical investigation results collected are within statistical conditions to demonstrate that primary and secondary endpoints are met and ultimately confirm the safety and efficacy of the Hylomate.
The innovative approach for non-invasive monitoring of fibrotic tissue formation using highresolution imaging (Figure 3) and the significant reduction visualized around Hylomate are the subject of an abstract submitted to the international conference of the European Heart Rhythm Association (EHRA– https://www.escardio.org/Congresses-Events/EHRA-Congress). The contribution will be presented by the Hylomate clinical study PI: Prof. Dr. MD. Christoph Starck.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Hylomate differs substantially from the current state of the art products regarding main function, mechanism of action, and product features. Hylomate fully exploits its unique material and the micro and nano engineering characteristics to block foreign body reaction ultimately providing the first-all-round solution to surgical pocket complication of implantable medical devices.

Through prevention of surgical pocket complications and the subsequent need for revision surgeries, Hylomate shall eliminate life-threatening risks for patients and enable a significant cut-down in healthcare costs, benefiting hospitals and health insurance organizations. Hylomate is the ideal improvement for the quality of care provided by surgeons and hospitals and the quality of life of patients. It shall impact health economics significantly reducing the overall healthcare costs.

picture1.jpg

picture2.jpg